Does the media refer more to NBIX or REGN?

In the previous week, Regeneron Pharmaceuticals had 27 more articles in the media than Neurocrine Biosciences. MarketBeat recorded 53 mentions for Regeneron Pharmaceuticals and 26 mentions for Neurocrine Biosciences. Neurocrine Biosciences' average media sentiment score of 1.07 beat Regeneron Pharmaceuticals' score of 0.60 indicating that Neurocrine Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neurocrine Biosciences 14 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Regeneron Pharmaceuticals 20 Very Positive mention(s) 3 Positive mention(s) 26 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ALNY or NBIX?

In the previous week, Neurocrine Biosciences had 4 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 26 mentions for Neurocrine Biosciences and 22 mentions for Alnylam Pharmaceuticals. Neurocrine Biosciences' average media sentiment score of 1.07 beat Alnylam Pharmaceuticals' score of 0.72 indicating that Neurocrine Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alnylam Pharmaceuticals 9 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Neurocrine Biosciences 14 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor NBIX or BIIB?

In the previous week, Neurocrine Biosciences had 4 more articles in the media than Biogen. MarketBeat recorded 26 mentions for Neurocrine Biosciences and 22 mentions for Biogen. Neurocrine Biosciences' average media sentiment score of 1.07 beat Biogen's score of 0.60 indicating that Neurocrine Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neurocrine Biosciences 14 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Biogen 11 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 4 Negative mention(s) 2 Very Negative mention(s) Positive

Does the media prefer INCY or NBIX?

In the previous week, Incyte had 4 more articles in the media than Neurocrine Biosciences. MarketBeat recorded 30 mentions for Incyte and 26 mentions for Neurocrine Biosciences. Incyte's average media sentiment score of 1.15 beat Neurocrine Biosciences' score of 1.07 indicating that Incyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Incyte 20 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Neurocrine Biosciences 14 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer UTHR or NBIX?

In the previous week, Neurocrine Biosciences had 3 more articles in the media than United Therapeutics. MarketBeat recorded 26 mentions for Neurocrine Biosciences and 23 mentions for United Therapeutics. United Therapeutics' average media sentiment score of 1.59 beat Neurocrine Biosciences' score of 1.07 indicating that United Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment United Therapeutics 18 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Neurocrine Biosciences 14 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Neurocrine Biosciences (NBIX) Competitors

$175.77 +1.62 (+0.93%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$174.75 -1.02 (-0.58%)

As of 07/24/2026 07:34 PM Eastern

Compare

NBIX vs. REGN, ALNY, BIIB, INCY, and UTHR

Should you buy Neurocrine Biosciences stock or one of its competitors? MarketBeat compares Neurocrine Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Neurocrine Biosciences include Regeneron Pharmaceuticals (REGN), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), Incyte (INCY), and United Therapeutics (UTHR). These companies are all part of the "biotechnology" industry.

How does Neurocrine Biosciences compare to Regeneron Pharmaceuticals?

Neurocrine Biosciences (NASDAQ:NBIX) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both large-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, profitability, media sentiment, earnings, dividends and institutional ownership.

Neurocrine Biosciences presently has a consensus target price of $194.05, indicating a potential upside of 10.40%. Regeneron Pharmaceuticals has a consensus target price of $787.88, indicating a potential upside of 20.10%. Given Regeneron Pharmaceuticals' higher possible upside, analysts plainly believe Regeneron Pharmaceuticals is more favorable than Neurocrine Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neurocrine Biosciences	0 Sell rating(s)	3 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.96
Regeneron Pharmaceuticals	0 Sell rating(s)	9 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.70

In the previous week, Regeneron Pharmaceuticals had 27 more articles in the media than Neurocrine Biosciences. MarketBeat recorded 53 mentions for Regeneron Pharmaceuticals and 26 mentions for Neurocrine Biosciences. Neurocrine Biosciences' average media sentiment score of 1.07 beat Regeneron Pharmaceuticals' score of 0.60 indicating that Neurocrine Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neurocrine Biosciences	14 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Regeneron Pharmaceuticals	20 Very Positive mention(s)	3 Positive mention(s)	26 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Regeneron Pharmaceuticals has higher revenue and earnings than Neurocrine Biosciences. Regeneron Pharmaceuticals is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neurocrine Biosciences	$2.86B	6.18	$478.60M	$6.49	27.08
Regeneron Pharmaceuticals	$14.34B	4.84	$4.50B	$41.04	15.98

Regeneron Pharmaceuticals has a net margin of 29.65% compared to Neurocrine Biosciences' net margin of 21.55%. Neurocrine Biosciences' return on equity of 19.79% beat Regeneron Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neurocrine Biosciences	21.55%	19.79%	13.82%
Regeneron Pharmaceuticals	29.65%	13.16%	10.17%

Neurocrine Biosciences has a beta of 0.39, indicating that its share price is 61% less volatile than the broader market. Comparatively, Regeneron Pharmaceuticals has a beta of 0.24, indicating that its share price is 76% less volatile than the broader market.

92.6% of Neurocrine Biosciences shares are owned by institutional investors. Comparatively, 83.3% of Regeneron Pharmaceuticals shares are owned by institutional investors. 4.6% of Neurocrine Biosciences shares are owned by insiders. Comparatively, 7.0% of Regeneron Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Neurocrine Biosciences beats Regeneron Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does Neurocrine Biosciences compare to Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals (NASDAQ:ALNY) and Neurocrine Biosciences (NASDAQ:NBIX) are both large-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, earnings, media sentiment, dividends, profitability and analyst recommendations.

93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. Comparatively, 92.6% of Neurocrine Biosciences shares are held by institutional investors. 0.9% of Alnylam Pharmaceuticals shares are held by insiders. Comparatively, 4.6% of Neurocrine Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Neurocrine Biosciences had 4 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 26 mentions for Neurocrine Biosciences and 22 mentions for Alnylam Pharmaceuticals. Neurocrine Biosciences' average media sentiment score of 1.07 beat Alnylam Pharmaceuticals' score of 0.72 indicating that Neurocrine Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alnylam Pharmaceuticals	9 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Neurocrine Biosciences	14 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Neurocrine Biosciences has lower revenue, but higher earnings than Alnylam Pharmaceuticals. Neurocrine Biosciences is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alnylam Pharmaceuticals	$3.71B	9.77	$313.75M	$3.66	74.25
Neurocrine Biosciences	$2.86B	6.18	$478.60M	$6.49	27.08

Alnylam Pharmaceuticals has a beta of 0.27, meaning that its share price is 73% less volatile than the broader market. Comparatively, Neurocrine Biosciences has a beta of 0.39, meaning that its share price is 61% less volatile than the broader market.

Neurocrine Biosciences has a net margin of 21.55% compared to Alnylam Pharmaceuticals' net margin of 11.72%. Alnylam Pharmaceuticals' return on equity of 85.76% beat Neurocrine Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alnylam Pharmaceuticals	11.72%	85.76%	10.32%
Neurocrine Biosciences	21.55%	19.79%	13.82%

Alnylam Pharmaceuticals currently has a consensus price target of $452.13, indicating a potential upside of 66.37%. Neurocrine Biosciences has a consensus price target of $194.05, indicating a potential upside of 10.40%. Given Alnylam Pharmaceuticals' higher probable upside, equities research analysts plainly believe Alnylam Pharmaceuticals is more favorable than Neurocrine Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alnylam Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.85
Neurocrine Biosciences	0 Sell rating(s)	3 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.96

Summary

Neurocrine Biosciences beats Alnylam Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Neurocrine Biosciences compare to Biogen?

Neurocrine Biosciences (NASDAQ:NBIX) and Biogen (NASDAQ:BIIB) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, risk, analyst recommendations, media sentiment, earnings and profitability.

Neurocrine Biosciences has a beta of 0.39, indicating that its share price is 61% less volatile than the broader market. Comparatively, Biogen has a beta of 0.16, indicating that its share price is 84% less volatile than the broader market.

92.6% of Neurocrine Biosciences shares are held by institutional investors. Comparatively, 87.9% of Biogen shares are held by institutional investors. 4.6% of Neurocrine Biosciences shares are held by insiders. Comparatively, 0.3% of Biogen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Neurocrine Biosciences had 4 more articles in the media than Biogen. MarketBeat recorded 26 mentions for Neurocrine Biosciences and 22 mentions for Biogen. Neurocrine Biosciences' average media sentiment score of 1.07 beat Biogen's score of 0.60 indicating that Neurocrine Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neurocrine Biosciences	14 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Biogen	11 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	4 Negative mention(s)	2 Very Negative mention(s)	Positive

Neurocrine Biosciences has a net margin of 21.55% compared to Biogen's net margin of 13.81%. Neurocrine Biosciences' return on equity of 19.79% beat Biogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neurocrine Biosciences	21.55%	19.79%	13.82%
Biogen	13.81%	12.83%	8.01%

Neurocrine Biosciences presently has a consensus target price of $194.05, indicating a potential upside of 10.40%. Biogen has a consensus target price of $220.57, indicating a potential upside of 9.09%. Given Neurocrine Biosciences' stronger consensus rating and higher probable upside, equities analysts plainly believe Neurocrine Biosciences is more favorable than Biogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neurocrine Biosciences	0 Sell rating(s)	3 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.96
Biogen	2 Sell rating(s)	12 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.53

Biogen has higher revenue and earnings than Neurocrine Biosciences. Biogen is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neurocrine Biosciences	$2.86B	6.18	$478.60M	$6.49	27.08
Biogen	$9.89B	3.02	$1.29B	$9.32	21.69

Summary

Neurocrine Biosciences beats Biogen on 14 of the 17 factors compared between the two stocks.

How does Neurocrine Biosciences compare to Incyte?

Incyte (NASDAQ:INCY) and Neurocrine Biosciences (NASDAQ:NBIX) are both large-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, media sentiment, risk, institutional ownership, earnings and analyst recommendations.

In the previous week, Incyte had 4 more articles in the media than Neurocrine Biosciences. MarketBeat recorded 30 mentions for Incyte and 26 mentions for Neurocrine Biosciences. Incyte's average media sentiment score of 1.15 beat Neurocrine Biosciences' score of 1.07 indicating that Incyte is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Incyte	20 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Neurocrine Biosciences	14 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Incyte currently has a consensus target price of $111.10, suggesting a potential downside of 5.58%. Neurocrine Biosciences has a consensus target price of $194.05, suggesting a potential upside of 10.40%. Given Neurocrine Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Neurocrine Biosciences is more favorable than Incyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Incyte	0 Sell rating(s)	14 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.36
Neurocrine Biosciences	0 Sell rating(s)	3 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.96

Incyte has a beta of 0.76, meaning that its share price is 24% less volatile than the broader market. Comparatively, Neurocrine Biosciences has a beta of 0.39, meaning that its share price is 61% less volatile than the broader market.

97.0% of Incyte shares are owned by institutional investors. Comparatively, 92.6% of Neurocrine Biosciences shares are owned by institutional investors. 16.2% of Incyte shares are owned by company insiders. Comparatively, 4.6% of Neurocrine Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Incyte has a net margin of 26.71% compared to Neurocrine Biosciences' net margin of 21.55%. Incyte's return on equity of 26.66% beat Neurocrine Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Incyte	26.71%	26.66%	19.77%
Neurocrine Biosciences	21.55%	19.79%	13.82%

Incyte has higher revenue and earnings than Neurocrine Biosciences. Incyte is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Incyte	$5.36B	4.39	$1.29B	$7.08	16.62
Neurocrine Biosciences	$2.86B	6.18	$478.60M	$6.49	27.08

Summary

Incyte beats Neurocrine Biosciences on 11 of the 17 factors compared between the two stocks.

How does Neurocrine Biosciences compare to United Therapeutics?

United Therapeutics (NASDAQ:UTHR) and Neurocrine Biosciences (NASDAQ:NBIX) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, profitability, risk, analyst recommendations, dividends and media sentiment.

94.1% of United Therapeutics shares are owned by institutional investors. Comparatively, 92.6% of Neurocrine Biosciences shares are owned by institutional investors. 8.6% of United Therapeutics shares are owned by company insiders. Comparatively, 4.6% of Neurocrine Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

United Therapeutics currently has a consensus price target of $648.33, indicating a potential upside of 22.68%. Neurocrine Biosciences has a consensus price target of $194.05, indicating a potential upside of 10.40%. Given United Therapeutics' higher possible upside, research analysts plainly believe United Therapeutics is more favorable than Neurocrine Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
United Therapeutics	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.85
Neurocrine Biosciences	0 Sell rating(s)	3 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.96

United Therapeutics has a beta of 0.58, suggesting that its share price is 42% less volatile than the broader market. Comparatively, Neurocrine Biosciences has a beta of 0.39, suggesting that its share price is 61% less volatile than the broader market.

United Therapeutics has a net margin of 40.62% compared to Neurocrine Biosciences' net margin of 21.55%. Neurocrine Biosciences' return on equity of 19.79% beat United Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
United Therapeutics	40.62%	19.24%	17.25%
Neurocrine Biosciences	21.55%	19.79%	13.82%

United Therapeutics has higher revenue and earnings than Neurocrine Biosciences. United Therapeutics is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
United Therapeutics	$3.18B	7.05	$1.33B	$27.09	19.51
Neurocrine Biosciences	$2.86B	6.18	$478.60M	$6.49	27.08

In the previous week, Neurocrine Biosciences had 3 more articles in the media than United Therapeutics. MarketBeat recorded 26 mentions for Neurocrine Biosciences and 23 mentions for United Therapeutics. United Therapeutics' average media sentiment score of 1.59 beat Neurocrine Biosciences' score of 1.07 indicating that United Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
United Therapeutics	18 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Neurocrine Biosciences	14 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

United Therapeutics beats Neurocrine Biosciences on 11 of the 17 factors compared between the two stocks.

Get Neurocrine Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NBIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NBIX vs. The Competition

Export

Metric	Neurocrine Biosciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$17.51B	$3.08B	$6.88B	$12.26B
Dividend Yield	N/A	2.07%	2.67%	9.80%
P/E Ratio	27.08	20.29	26.99	23.71
Price / Sales	6.18	353.86	492.47	76.53
Price / Cash	34.74	27.62	50.54	59.64
Price / Book	5.39	4.13	10.28	6.07
Net Income	$478.60M	$65.94M	$3.60B	$331.84M
7 Day Performance	2.86%	-4.18%	-1.25%	-1.53%
1 Month Performance	7.06%	-3.76%	-0.35%	-2.46%
1 Year Performance	33.02%	9.93%	18.41%	13.66%

Neurocrine Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NBIX Neurocrine Biosciences	4.5221 of 5 stars	$175.77 +0.9%	$194.05 +10.4%	+33.5%	$17.51B	$2.86B	27.08	2,000	News Coverage Positive News Upcoming Earnings Analyst Forecast
REGN Regeneron Pharmaceuticals	4.4558 of 5 stars	$663.09 -0.2%	$787.67 +18.8%	+16.2%	$70.25B	$14.34B	16.16	15,410	Trending News Upcoming Earnings Analyst Forecast
ALNY Alnylam Pharmaceuticals	4.6076 of 5 stars	$288.06 -3.6%	$457.57 +58.8%	-17.1%	$39.89B	$3.71B	78.70	2,770	News Coverage Upcoming Earnings Analyst Forecast
BIIB Biogen	3.9253 of 5 stars	$209.03 +5.0%	$220.04 +5.3%	+52.5%	$29.40B	$9.89B	22.43	7,500	Upcoming Earnings Analyst Forecast
INCY Incyte	3.1897 of 5 stars	$114.23 -2.1%	$109.10 -4.5%	+66.9%	$23.32B	$5.14B	16.13	2,844	Positive News Upcoming Earnings Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NBIX) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Neurocrine Biosciences (NBIX) Competitors

NBIX vs. REGN, ALNY, BIIB, INCY, and UTHR

How does Neurocrine Biosciences compare to Regeneron Pharmaceuticals?

Summary

How does Neurocrine Biosciences compare to Alnylam Pharmaceuticals?

Summary

How does Neurocrine Biosciences compare to Biogen?

Summary

How does Neurocrine Biosciences compare to Incyte?

Summary

How does Neurocrine Biosciences compare to United Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NBIX vs. The Competition

Neurocrine Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Neurocrine Biosciences (NBIX) Competitors

NBIX vs. REGN, ALNY, BIIB, INCY, and UTHR

How does Neurocrine Biosciences compare to Regeneron Pharmaceuticals?

Do analysts rate NBIX or REGN?

Does the media refer more to NBIX or REGN?

Which has stronger earnings and valuation, NBIX or REGN?

Is NBIX or REGN more profitable?

Which has more risk and volatility, NBIX or REGN?

Do institutionals & insiders have more ownership in NBIX or REGN?

Summary

How does Neurocrine Biosciences compare to Alnylam Pharmaceuticals?

Do institutionals & insiders have more ownership in ALNY or NBIX?

Does the media favor ALNY or NBIX?

Which has better valuation and earnings, ALNY or NBIX?

Which has more volatility & risk, ALNY or NBIX?

Is ALNY or NBIX more profitable?

Do analysts rate ALNY or NBIX?

Summary

How does Neurocrine Biosciences compare to Biogen?

Which has more risk and volatility, NBIX or BIIB?

Do institutionals & insiders believe in NBIX or BIIB?

Does the media favor NBIX or BIIB?

Is NBIX or BIIB more profitable?

Do analysts rate NBIX or BIIB?

Which has better valuation and earnings, NBIX or BIIB?

Summary

How does Neurocrine Biosciences compare to Incyte?

Does the media prefer INCY or NBIX?

Do analysts rate INCY or NBIX?

Which has more volatility & risk, INCY or NBIX?

Do institutionals and insiders have more ownership in INCY or NBIX?

Is INCY or NBIX more profitable?

Which has better earnings and valuation, INCY or NBIX?

Summary

How does Neurocrine Biosciences compare to United Therapeutics?

Do institutionals & insiders have more ownership in UTHR or NBIX?

Do analysts recommend UTHR or NBIX?

Which has more volatility & risk, UTHR or NBIX?

Is UTHR or NBIX more profitable?

Which has higher earnings & valuation, UTHR or NBIX?

Does the media prefer UTHR or NBIX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NBIX vs. The Competition

Neurocrine Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools